1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: 
Costs and outcomes associated with selecting patients for IV tPA treatment with CTP versus CT scanning base-case results
Outcome (per patient) Usual Care CTP
% of patients with ischemic stroke treated 28.30% 20.94%
% of all patients with stroke treated 24.62% 18.22%
% of all patients with stroke who receive CTP 0.00% 49.42%
Favorable outcome (mRS, 0.1) 39.44% 40.03%
mRS outcomes for patients with ischemic stroke 
% with 90-day mRS 0 18.41% 18.23%
% with 90-day mRS 1 21.03% 21.80%
% with 90-day mRS 2 12.56% 11.96%
% with 90-day mRS 3 13.14% 13.27%
% with 90-day mRS 4 15.75% 16.13%
% with 90-day mRS 5 7.13% 6.78%
% dead at 90 days 11.98% 11.83%
Life-years 0.2115 0.2119
QALYs 0.1241 0.1246
Hospitalization costs (including SICH) (in US $) $11,400 $11,358
Novel diagnostic costs (in US $) $0 $236
Drug costs (in US $) $1,070 $792
Total costs (in US $) $12,470 $12,386
Incremental cost per life-year gained (in US $) – Cost-saving
Incremental cost per QALY gained (in US $) – Cost-saving
Incremental cost per major disability avoided (mRS, ≥3) (in US $) Cost-saving